Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wilms' tumor 1-derived peptide-human leukocyte antigen (WT1-derived peptide-HLA) complexes represent a class of cell-surface tumor-associated antigens. Wilms' tumor 1 (WT1) is an intracellular zinc-finger transcription factor that is highly overexpressed in various hematological malignancies (such as acute myeloid leukemia and myelodysplastic syndromes) and solid tumors (including ovarian cancer, mesothelioma, and glioblastoma), while showing very limited expression in normal adult tissues. Because WT1 is an intracellular protein, it cannot be targeted by conventional monoclonal antibodies. However, intracellular WT1 is processed by the proteasome into immunogenic peptides (such as the RMFPNAPYL or CYTWNQMNL epitopes) and presented on the cell surface in complex with HLA class I molecules (such as HLA-A*02:01 or HLA-A*24:02). These peptide-HLA complexes can be recognized by the T-cell receptors (TCRs) of cytotoxic CD8+ T cells.
Therapeutic strategies targeting WT1-derived peptide-HLA complexes include TCR-engineered T-cell (TCR-T) therapies, chimeric antigen receptor (CAR) T-cell therapies utilizing TCR-mimic (TCRm) antibodies, and bispecific or trispecific T-cell engagers. TCRm antibodies, such as ESK1, ESK2, and ESK3, are engineered to bind specifically to the peptide-HLA complex with high affinity, mimicking TCR specificity while offering the pharmacological advantages of antibodies. Other agents, such as CUE-102, are fusion proteins designed to selectively expand WT1-specific T cells. Key challenges in targeting these complexes include potential off-target cross-reactivity with homologous self-peptides (e.g., PIGQ or M13L), on-target off-tumor toxicity in tissues with low WT1 expression, and tumor immune evasion through antigen escape or loss of HLA expression.
Drugs targeting WT1-derived peptide-HLA complexes act by binding specifically to the peptide-MHC complex on the cell surface, mimicking T-cell receptor (TCR) recognition. This binding triggers immune-mediated destruction of the target tumor cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), direct T-cell engagement and activation (via bispecific or trispecific T-cell engagers), or direct cytotoxicity by engineered T cells (such as TCR-T or CAR-T cells). Additionally, peptide-MHC fusion proteins can selectively bind and expand endogenous WT1-specific T cells to enhance the anti-tumor immune response.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wilms' tumor 1-derived peptide-human leukocyte antigen complexes (WT1-derived peptide-HLA complexes).